Clovis Oncology, Inc. (CLVS) Stock: A Biotech Stock That’s Climbing


Clovis Oncology, Inc. (CLVS) is working its way for to the top in the market today. The stock, focused on the biotech sector, is currently trading at $6.00 after climbing 0.00% so far today. As it relates to biotech companies, there are several aspects that have the ability to generate movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent headlines surrounding CLVS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-04-19 06:00AM Near an All-Time Low, Is Clovis Oncology a Buy?
Aug-31-19 09:32AM Why Is Clovis (CLVS) Down 36.8% Since Last Earnings Report?
Aug-28-19 08:05AM Clovis Oncology to Present at 2019 Wells Fargo Healthcare Conference
Aug-22-19 05:42PM Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Companys 4.50% Convertible Senior Notes Due 2024
Aug-19-19 10:15AM Clovis Oncology Inc (CLVS) President and CEO Patrick J Mahaffy Bought $279,500 of Shares

However, when making a decision with regard to investing, investors should look at much more than news, this is especially the case in the generally speculative biotechnology space. Here’s what’s happing when it comes to Clovis Oncology, Inc..

Recent Movement Out of CLVS

While a gain in a single session, like the gain that we’re seeing from Clovis Oncology, Inc. might lead to excitement in some investors, a single session move alone shouldn’t be the basis of a decision to, or not to, invest in a company. It’s always a good idea to look into trends experienced by the stock further out than a single trading session. As it relates to CLVS, here are the returns that investors have seen:

  • Weekly – In the last 5 trading sessions, CLVS has produced a price change that amounts to 15.83%.
  • Monthly – The monthly performance from Clovis Oncology, Inc. has been 5.63%.
  • Past Three Months – Throughout the past 3 months, the company has produced a ROI of -56.30%
  • Past 6 Months – Over the last six months, we’ve seen a change that works out to -78.59% from the stock.
  • This Year So Far – Since the close of last year CLVS has resulted in a ROI of -66.59%.
  • Full Year – Lastly, over the last full year, investors have seen performance of -82.95% from CLVS. Over this period, the stock has traded at a high price of -83.26% and a low of 20.48%.

Ratios Worth Watching

Digging into a few ratios having to do with a company can give investors a view of how dangerous and/or potentially profitable a stock pick might be. Here are a few of the most important ratios to consider when digging into CLVS.

Short Ratio – The short ratio is a measure of short interest. As the short ratio goes higher, it means that more investors are expecting that the price of the stock is going to go down. Across the sector, biotech stocks can carry a higher short ratio. On the other hand, we also see quite a few short squeezes in the industry. Nonetheless, when it comes to Clovis Oncology, Inc., the stock’s short ratio amounts to 5.61.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure If a company is able to pay its debts when they come due using quick assets or current assets. In the biotechnology sector, many companies are reliant on the continuation of investor support, these ratios can seem bad. Nonetheless, quite a few better companies in the biotech space do have strong current and quick ratios. As it relates to CLVS, the quick and current ratios work out to 3.30 and 3.60 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets currently owned by the company to the price of shares. when it comes to Clovis Oncology, Inc., the book to share value ratio is -0.57.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the value of the company’s stock. Many early stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology industry, this is an important ratio to consider. In this case, the cash to share value works out to 5.83.

How Analysts Feel About Clovis Oncology, Inc.

Although it’s never a smart idea to blindly follow the opinions of analysts, it is a good idea to use their opinions when validating your own due diligence before making an investment decision in the biotech space. Here are the recent moves that we’ve seen from analysts when it comes to CLVS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-13-19 Downgrade BofA/Merrill Buy → Neutral
Aug-02-19 Downgrade Guggenheim Buy → Neutral
May-29-19 Downgrade Goldman Neutral → Sell
Apr-15-19 Reiterated H.C. Wainwright Buy $39 → $37
Feb-13-19 Initiated H.C. Wainwright Buy $40

What Institutions And Insiders Think Of Clovis Oncology, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CLVS, here’s what we’re seeing:

  • Institutions – Currently, institutions hold 0 of CLVS. On the other hand, it’s worth considering that the ownership held by institutions has seen a move in the amount of 4.22% over the past quarter.
  • Insider Holdings – When it comes to insiders, insiders of the company currently hold 2.50% of the company. Their ownership of the company has moved 6.34% in the last 3 months.

A Look At Share Counts

Investors and traders seem to have a heavy interest in the amounts of shares both outstanding and available. With respect to Clovis Oncology, Inc., currently there are 54.14M and there is a float of 52.93M. These data mean that out of the total of 54.14M shares of CLVS in existence today, 52.93M are available to be traded on the public market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CLVS, the short percent of the float is 33.01%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-5.80. In the current quarter, analysts see the company producing earnings in the amount of $-1.84. Over the last 5 years, CLVS has generated revenue in the amount of $0 with earnings coming in at -19.10%. On a quarter over quarter basis, earnings have seen movement of -17.20% and revenue has seen movement of 38.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. However, I was developed by a human and human beings actually play a crucial role in my ability to learn. Sure, I can dig through social trends and other publicly available information, but, like humans, I learn much faster when I have the help of a teacher. If you would to help me learn something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at data? If so, write a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here